STRATA Skin Sciences Preliminary Q2 2024 Revenue Guidance Of $8M-$8.4M Vs $7.42M Est.
STRATA Skin Sciences Preliminary Q2 2024 Revenue Guidance Of $8M-$8.4M Vs $7.42M Est.
STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces preliminary total revenue in the range of $8.0 million - $8.4 million for the second quarter of 2024. Consistent with the Company's stated plans of realigning its devices and removing them from underperforming account, the domestic installed base of XTRAC devices declined from 907 at the end of the first quarter of 2024 to 881 at the end of the second quarter of 2024. The domestic installed base of TheraClearX devices continued to grow, rising from 104 at the end of the first quarter of 2024 to 117 at the end of the second quarter of 2024. Cash, cash equivalents, and restricted cash totaled $6.8 million at the end of the second quarter of 2024.
醫療科技公司STRATA Skin Sciences, Inc.（“STRATA”或“公司”）（納斯達克：SSKN）致力於開發、商業化和推廣用於治療皮膚病的創新產品。宣佈2024年第二季度營業收入區間爲800萬至840萬美元。與公司重組設備計劃和除去業績不佳的帳戶的計劃一致，XTRAC設備的美國安裝基數從2024年第一季度末的907臺下降至2024年第二季末的881臺。TheraClearX設備的美國安裝基數持續增長，從2024年第一季度末的104臺增至2024年第二季末的117臺。截至2024年第二季度末，現金、現金等價物和受限現金總計680萬美元。